Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Einat Avishai"'
Autor:
Shadan Lalezari, Assaf A. Barg, Rima Dardik, Jacob Luboshitz, Dalia Bashari, Einat Avishai, Gili Kenet
Publikováno v:
TH Open, Vol 05, Iss 02, Pp e183-e187 (2021)
Aim Very little is known regarding reproductive choices, pregnancy, and delivery of women with moderate to severe hemophilia. Our aim was to describe our experience with three hemophiliac women and their journey to achieve motherhood. Methods Medical
Externí odkaz:
https://doaj.org/article/4483145807e0428c90908a643c4f5166
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
D. Bashari, Einat Avishai, Tami Brutman-Barazani, Tami Livnat, Gili Kenet, Amir A. Kuperman, Mudi Misgav, Ivan Budnik, Assaf A. Barg, Aaron Lubetsky
Publikováno v:
Haemophilia. 27:383-391
Introduction Real-world data on prophylaxis of severe haemophilia A (HA) patients treated by emicizumab are scarce. Aim To study the efficacy and safety of longitudinal emicizumab prophylaxis and assess laboratory monitoring correlations in a large p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac461d3d569b848101cd3e2d280a777a
https://doi.org/10.1111/hae.14318
https://doi.org/10.1111/hae.14318
Autor:
Gili Kenet, Einat Avishai, Ivan Budnik, Tami Brutman-Barazani, Jonathan Schapiro, Assaf A. Barg, Dalia Bashari, Mudi Misgav, A. Lubetsky, Tami Livnat
Publikováno v:
Haemophilia. 27:253-260
Introduction Emicizumab (Hemlibra™) is approved for prophylaxis of Haemophilia A (HA) patients with and without inhibitors. However, real-world data on emicizumab use in the elderly HA patients with concomitant cardiovascular risk factors are lacki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::165d4bec786c6a57c9791364601da456
https://doi.org/10.1111/hae.14261
https://doi.org/10.1111/hae.14261
Autor:
Sarina Levy-Mendelovich, Atar Lev, Einat Avishai, Ivan Budnik, Rima Dardik, Asaaf Arie Barg, Raz Somech, Gili Kenet
Publikováno v:
Pediatric research.
Hemophilia A (HA) therapy requires intravenous replacement infusions of factor (F) VIII concentrate. Inhibitors are high-affinity immunoglobulin G that are directed against FVIII and thereby render replacement therapy ineffective. This complication h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb3a723ddd972e5484254a9bd703175
https://pubmed.ncbi.nlm.nih.gov/36045224
https://pubmed.ncbi.nlm.nih.gov/36045224
Autor:
Tami Brutman-Barazani, Mudi Misgav, Assaf Arie Barg, Einat Avishai, Ivan Budnik, Sarina Levy-Mendelovich, Gili Kenet, Tami Livnat, Tamara Levy
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 4303, p 4303 (2021)
Journal of Clinical Medicine
Volume 10
Issue 19
Journal of Clinical Medicine
Volume 10
Issue 19
Emicizumab (Hemlibra™) is approved for prophylaxis of hemophilia A (HA) patients. The HAVEN studies addressed bleeding reduction in emicizumab-treated patients, but real-world data on bleeding patterns during emicizumab therapy are lacking. We aime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12ecef4f7d8d811b83728dfd73fc0849
https://www.mdpi.com/2077-0383/10/19/4303
https://www.mdpi.com/2077-0383/10/19/4303
Autor:
Tami Livnat, Yulia Khavkin, Gili Kenet, Einat Avishai, Assaf A. Barg, Shadan Lalezari, Ivan Budnik, Rima Dardik, Sarina Levy-Mendelovich, Ortal Barel
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 9074, p 9074 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 16
International Journal of Molecular Sciences
Volume 22
Issue 16
Introduction: Hemophilia A (HA) is an X-linked bleeding disorder caused by factor VIII (FVIII) deficiency or dysfunction due to F8 gene mutations. HA carriers are usually asymptomatic because their FVIII levels correspond to approximately half of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfa2bf17b9e8f618a006cdc666ea2098
https://www.mdpi.com/1422-0067/22/16/9074
https://www.mdpi.com/1422-0067/22/16/9074
Autor:
Ivan Budnik, D. Bashari, Einat Avishai, Ophira Salomon, Tami Livnat, Rima Dardik, Ilia Tamarin
Publikováno v:
Thrombosis and Haemostasis. 119:1927-1932
Background Factor XI (FXI) deficiency is a rare autosomal bleeding disorder. The rarity of spontaneous bleeding and absence of optimal tools to predict the bleeding risk in FXI-deficient patients hamper the standardization of prophylactic treatment e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40fe272c0fd62447359115ae8aff811a
https://doi.org/10.1055/s-0039-1696685
https://doi.org/10.1055/s-0039-1696685
Autor:
Assaf A, Barg, Tami, Brutman-Barazani, Einat, Avishai, Ivan, Budnik, Omri, Cohen, Rima, Dardik, Sarina, Levy-Mendelovich, Tami, Livnat, Gili, Kenet
Publikováno v:
Blood Cells, Molecules, and Diseases. 95:102663
Rare bleeding disorders (RBD) are inherited coagulopathies, whose hemostatic control is based upon replacement therapy. Marstacimab (PF-06741086) is a human monoclonal IgG that targets the Kunitz2 domain of tissue factor pathway inhibitor [TFPI]. Mar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d19791bb4ded30ce1ab8b090655730c0
https://doi.org/10.1016/j.bcmd.2022.102663
https://doi.org/10.1016/j.bcmd.2022.102663
Autor:
Assaf Arie Barg, Ilia Tamarin, Tami Livnat, Shadan Lalezari, Ivan Budnik, Mudi Misgav, Rima Dardik, Einat Avishai, Gili Kenet, Aharon Lubetsky, D. Bashari, Tamar Barazani Brutman
Publikováno v:
Blood cells, moleculesdiseases. 87
Background Severe von Willebrand disease (VWD) may be associated with chronic joint damage and may require prophylactic therapy. Emicizumab is a humanized bispecific antibody, which mimics the function of coagulation factor VIII (FVIII), and it has b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b7c02316d2f80083c405f52a8a298ab
https://pubmed.ncbi.nlm.nih.gov/33341070
https://pubmed.ncbi.nlm.nih.gov/33341070